Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00519662 · ClinicalTrials.gov registry record · Phase 1

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

A Phase 1 study, sponsored by Sunesis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
32
Enrollment target

NCT00519662 is a Phase 1 study that has completed, run by Sunesis Pharmaceuticals. The registered enrollment target is 32 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00519662, a Phase 1 study, has completed, sponsored by Sunesis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
32 participants
Enrollment target

Study Summary

This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

Interventions

  • DRUG SNS-314

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2007-08
Est. Completion 2009-03
Phase Phase 1

Sponsor

Sunesis Pharmaceuticals

13 total trials

What the Registry Record Tells You About NCT00519662

The ClinicalTrials.gov registry entry for NCT00519662 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sunesis Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which SNS-314 is the first listed.

NCT00519662 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00519662 about?

NCT00519662 is a clinical study titled "Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors". This is a study to assess the safety and tolerability of SNS-314 in advanced solid tumors in humans.

What is the current status of trial NCT00519662?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2007-08. Estimated completion is 2009-03.

What interventions are being tested in trial NCT00519662?

The interventions under investigation include: SNS-314 (DRUG).

Who is sponsoring clinical trial NCT00519662?

This trial is sponsored by Sunesis Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.